Archemix also announced that Page Bouchard, senior vice president at the company, will head the research and preclinical development group. Bouchard joined Archemix in 2004 as senior vice president of preclinical drug discovery and preclinical development.
Rebecca Galler Robison, Stephan Herrera, Robert Schaub, Page Bouchard
Rebecca Galler Robison, senior director of corporate strategy for Sirna Therapeutics, has left the RNAi drug developer. Assuming her duties is Stephan Herrera, who has become Sirna’s executive director of investor relations.
According to Herrera, Robison’s departure was linked to Sirna’s ongoing relocation of employees from its former headquarters on Boulder, Colo., to its new headquarters in San Francisco.
Aptamer drug development firm Archemix said this week that it has appointed Robert Schaub as vice president of preclinical discovery.
Schaub, who was most recently assistant vice president for cardiovascular and metabolic diseases at Wyeth, holds a bachelor's degree in biology from the University of Nevada and a PhD from Washington State University, the company said.